Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLH11811 in advanced EGFR-mutated NSCLC
NCT05555212Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of QLH11811 in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Safety parameters at 2 years and Objective Response Rate at 2 years. Started Oct 2022; status: recruiting.
02
Drugs
QLH11811
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05555212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05555212.